DOI
https://doi.org/10.47689/2181-1415-vol4-iss5/S-pp310-316Ключевые слова
гипертрофическая кардиомиопатия / ремоделирование сердца / операция МорроуАннотация
В данной статье приведены данные о больных с обструктивной формой гипертрофической кардиомиопатии после проведенной миоэктомии по Морроу и особенности ремоделирования сердца.
Скачивания
Библиографические ссылки
Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., Александрова С.А., Берсенева М.И., Гордеев М.Л., Дземeшкевич С.Л., Заклязьминская Е.В., Иртюга О.Б., Каплунова В.Ю., Костарева А.А., Крутиков А.Н., Маленков Д.А.,
Новикова Т.Н., Саидова М.А., Санакоев М.К., Стукалова О.В. Гипертрофическая кардиомиопатия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(5):4541. doi:10.15829/1560-4071-2021-4541 2020
ACCF/AHA Pocket Guideline Adapted from the 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy November 2011 ACCF/AHA Pocket Guideline Adapted from the 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy November 2011
Осиев А.Г., Найденов Р.А. Кретов Е.И., Обединская Н.Р., Курбатов В.П., Гипертрофическая обструктивная кардиомиопатия, Альманах клинической медицины. 2015 Апрель-май; 38: 95-104
Brian A. Houston and Gerin R. Stevens, Hypertrophic Cardiomyopathy: AReview. Clinical Medicine Insights: Cardiology 2014:8(S1) 53-65 doi: 10.4137/CMC.S15717
Robert A. Leonardi, Evan P. Kransdorf, David L. Simel and Andrew Wang. Meta-Analyses of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy Comparative Rates of Overall Mortality and Sudden Cardiac Death After Treatment // Circ. Cardiovasc. Interv. 2010. Vol. 3. P. 97-104.
Richardson P., McKenna W., Bristow M. et al. Report of the 1995 WHO/ISFC Task Force on the Defi nition and Classifi cation of Cardiomyopathies // Circulation. 1996. Vol. 93. P. 841–842.
Laennec R. De l’auscultation me´diate, ou traite´ du diagnostic des maladies des poumons et du coeur, fonde principalement sur ce nouveau moyen d’exploration. Paris, 1819
Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104(4):557-567
Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J Clin Invest. 1992;90(5):1666-1671. https://doi.org/10.1172/JCI116038
Ackerman MJ, Van Driest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol. 2002;39(12):2042-2048.
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-2524.
Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation. 2010;122(23):2430-2440; discussion 2440. https://doi.org/10.1161/CIRCULATIONAHA.110.978924
Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102(8):858-864.
Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(3):201-211. https://doi.org/10.1016/j.jacc.2009.02.075
Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosinbinding protein C gene mutations. J Am Coll Cardiol. 2001;38(2): 315-321.
Wheeler M, Pavlovic A, DeGoma E, Salisbury H, Brown C, Ashley EA. A new era in clinical genetic testing for hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2(4):381-391. https://doi.org/10.1007/s12265-009-9139-0
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785-789.
Petrone RK, Klues HG, Panza JA, Peterson EE, Maron BJ. Coexistence of mitral valve prolapse in a consecutive group of 528 patients with hypertrophic cardiomyopathy assessed with echocardiography. J Am Coll Cardiol. 1992;20(1):55-61.
Gersh BJ, Maron BJ, Bonow RO 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy; Elliott PM, Anastasakis A, Borger MA, Borggrefe 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)
Long-Term Clinical Course and Symptomatic Statusof Patients after Operation for Hypertrophic Subaortic StenosisBarry J. Maron, M.D., Walter H. Merrill, M.D., Paul A. Freier, B.A.,Kenneth M. Kent, M.D., PH.D., Stephen E. Epstein, M.D., Andrew G. Morrow, M.D., Circulation, Vol. 57, No 6, June 1978
James J. Wu & Michael Seco & Caroline Medi & Chris Semsarian & David R.Richmond & Joseph A. Dearani & Hartzell V. Schaff &Michael J. Byrom & Paul G. Bannon, Surgery for hypertrophic cardiomyopathy, Biophys Rev (2015) 7:117–125
Загрузки
112 47Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2023 Тимур Абдуллаев , Хуршид Фозилов , Наргис Расулова , Саодат Мирзарахимова , Игорь Цой (Автор)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
